APA (7th ed.) Citation

N, A., F, L., E, B., J, L., F, L., D, D., . . . R, H. (2025). Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial). Immuno-oncology technology, 29, 101077. https://doi.org/10.1016/j.iotech.2025.101077

Chicago Style (17th ed.) Citation

N, Alshatti, et al. "Phase I(b) Study Evaluating the Safety and Efficacy of Intratumoral Agonistic Anti-CD40 (selicrelumab) in Combination with Anti-PD-L1 (atezolizumab) in Patients with Refractory or Relapsed B-cell Lymphoma (ITSELF Trial)." Immuno-oncology Technology 29 (2025): 101077. https://doi.org/10.1016/j.iotech.2025.101077.

MLA (9th ed.) Citation

N, Alshatti, et al. "Phase I(b) Study Evaluating the Safety and Efficacy of Intratumoral Agonistic Anti-CD40 (selicrelumab) in Combination with Anti-PD-L1 (atezolizumab) in Patients with Refractory or Relapsed B-cell Lymphoma (ITSELF Trial)." Immuno-oncology Technology, vol. 29, 2025, p. 101077, https://doi.org/10.1016/j.iotech.2025.101077.